This article reports the pharmacotherapy process of a clinical pharmacist participating in the treatment of a patient with acute liver injury caused by intravenous injection of amiodarone and pulmonary embolism-induced heart failure. The patient had heart failure complicated with pulmonary embolism and systemic congestion and then developed into acute liver injury, which was aggravated and had the risk of cirrhosis. At the same time, the patient developed drug-induced liver injury due to intravenous injection of amiodarone, which interfered with the clinical formulation of treatment plans. The clinician strengthened treatments of anti-heart failure, anticoagulation, reduction of pulmonary artery pressure and others to relieve the pathological factors of cardiogenic liver injury. The clinical pharmacist suggested stopping amiodarone to exclude the factors of drug-induced liver injury, the clinician adopted the suggestion, and finally the patient's condition was stable and the liver function improved. The analysis of this patient’s liver injury and assisting the clinical adjustment of medication are important contents of pharmaceutical monitoring. This article can provide a reference for the diagnosis and treatment of similar cases of acute liver injury.

1.罗昌彬,程玲霞,黄文彬,等. 综合淤血评分预测急诊重症监护室急性心力衰竭患者180天不良事件发生的临床价值研究[J]. 华西医学, 2022, 37(12): 1824-1830. [Luo CB, Cheng LX, Huang WB, et al. Clinical value of composite congestion score in predicting adverse events in patients with acute heart failure in emergency intensive care unit within 180 days[J]. West China Medical Journal, 2022, 37(12): 1824-1830.] DOI: 10.7507/1002-0179.202210165.

2.王笛琨,张丽晖,国志尊,等. 肝纤维化评价指标对心力衰竭预后价值的研究进展[J]. 中华老年多器官疾病杂志, 2024, 23(5): 386-389. [Wang DK, Zhang  LH, Guo ZZ, et al.Ｒesearch progress on prognostic value of evaluation indexes of hepatic fibrosis for heart failure[J]. Chinese Journal of Multiple Organ Diseases in the Elderly, 2024, 23(5): 386-389.] DOI: 10.11915/j.issn. 1671-5403.2024.05.084.

3.Xanthopoulos A, Starling RC, Kitai T, et al. Heart failure and liver disease: cardiohepatic interactions[J]. JACC Heart Fail, 2019, 7(2): 87-97. DOI: 10.1016/j.jchf.2018.10.007. 

4.Samsky MD, Patel CB, Dewald TA, et al. Cardiohepatic interactions in heart failure: an overview and clinical implications[J]. J Am Coll Cardiol, 2013, 61(24): 2397-2405. DOI: 10.1016/j.jacc.2013.03.042.

5.张学云,郑松柏. 他汀类药物所致肝功能异常及其处理策略[J]. 中国新药与临床杂志, 2021, 40(4): 246-250. [Zhang XY, Zheng SB. Liver dysfunction caused by statins and its treatment strategy[J]. Chinese Journal of New Drugs and Clinical Remedies, 2021, 40(4): 246-250.] DOI: 10.14109/j.cnki.xyylc.2021.04.02.

6.Essrani R, Mehershahi S, Essrani RK, et al. Amiodarone-induced acute liver injury[J]. Case Rep Gastroenterol, 2020, 14(1): 87-90. DOI: 10.1159/000506184.

7.Mohamed M, Al-Hillan A, Flores M, et al. Concomitant acute hepatic failure and renal failure induced by intravenous amiodarone: a case report and literature review[J]. Gastroenterology Res, 2020, 13(1): 40-43. DOI: 10.14740/gr1254.

8.杨欣,袁世加,周杭,等. 胺碘酮注射液致急性肝衰竭1例[J]. 中国临床药学杂志, 2022, 31(1): 64-66. [Yang  X, Yuan SJ, Zhou H, et al. A case of amiodarone injection-Induced acute liver injury[J]. Chinese Journal Of Clinical Pharmacy, 2022, 31(1): 64-66.] DOI: 10.19577/j.1007-4406.2022.01.014.

9.曲婉彤,李禹慧,石妍玉,等. 心力衰竭患者静脉注射胺碘酮致急性肝损伤1例报告及临床分析[J]. 长春中医药大学学报, 2021, 37(1): 149-152. [Qu WT, Li YH, Shi YY, et al. A case report and clinical analysis of acute liver injury caused by intravenous amiodarone in a patient with heart failure[J]. Journal of Changchun University of Chinese Medicine, 2021, 37(1): 149-152.] DOI: 10.13463/j.cnki.cczyy.2021.01.040.

10.姜东莉,李锐,尹鹏. 胺碘酮注射液致急性肝损伤1例[J]. 中国实验诊断学, 2021, 25(10): 1579-1580. [Jiang  DL, Li R, Yin P. A case of amiodarone injection-Induced acute liver injury[J]. Chinese Journal of Laboratory Diagnostics, 2021, 25(10): 1579-1580.] DOI: 10.3969/j.issn.1007-4287.2021.10.046.

11.马嘉蹊,姚甜甜,程浩,等. 不同评估量表在药物性肝损伤中的诊断价值分析[J]. 临床肝胆病杂志, 2024, 40(6): 1203-1208. [Ma JX, Yao TT, Cheng H, et al. Value of different assessment scales in the diagnosis of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(6): 1203-1208.] DOI: 10.12449/JCH240621.

12.Naranjo CA, Shear NH, Lanctôt KL. Advances in the diagnosis of adverse drug reactions[J]. J Clin Pharmacol, 1992, 32(10): 897-904. DOI: 10.1002/j.1552-4604.1992.tb04635.x.

13.中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-273. DOI: 10.3760/cma.j.cn112148-20231101-00405.

14.中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1): 11-51. DOI: 10.3760/cma.j.cn112137-20201008-02778.

15.Velayati A, Valerio MG, Shen M, et al. Update on pulmonary arterial hypertension pharmacotherapy[J]. Postgrad Med, 2016, 128(5): 460-473. DOI: 10.1080/ 00325481.2016.1188664.

16.谢春玲. 地尔硫卓治疗肺心病肺动脉高压的临床疗效观察[J]. 实用心脑肺血管病杂志, 2012, 20(6): 1020-1021. [Xie CL. Clinical efficacy of diltiazem in the treatment of pulmonary heart disease and pulmonary arterial hypertension[J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2012, 20(6): 1020-1021.] DOI: CNKI:SUN:SYXL.0.2012-06-051.

17.中华医学会心血管病学分会肺血管病学组. 急性肺栓塞诊断与治疗中国专家共识(2015)[J]. 中华心血管病杂志, 2016, 44(3): 197-211. DOI: 10.3760/cma.j.issn. 0253-3758.2016.03.005.

18.中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组. 肺血栓栓塞症诊治与预防指南[J]. 中华医学杂志, 2018, 98(14): 1060-1087. DOI: 10.3760/cma.j.issn.0376-2491.2018. 14.007.

19.中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6): 572-618. DOI: 10.3760/cma.j.cn112148-20230416-00221.